Arbutus Biopharma Corporation
ABUS
$2.71
$0.031.12%
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -53.95% | 0.15% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -53.95% | 0.15% | |||
| Cost of Revenue | -12.92% | 14.00% | |||
| Gross Profit | 0.59% | -18.94% | |||
| SG&A Expenses | -12.68% | -2.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.86% | 9.88% | |||
| Operating Income | 3.90% | -12.26% | |||
| Income Before Tax | 3.94% | -17.61% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 3.94% | -17.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.94% | -17.61% | |||
| EBIT | 3.90% | -12.26% | |||
| EBITDA | 3.92% | -12.34% | |||
| EPS Basic | 4.50% | -16.62% | |||
| Normalized Basic EPS | 4.58% | -11.24% | |||
| EPS Diluted | 3.67% | -16.62% | |||
| Normalized Diluted EPS | 4.58% | -11.24% | |||
| Average Basic Shares Outstanding | 0.64% | 0.87% | |||
| Average Diluted Shares Outstanding | 0.64% | 0.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
